Recent QLGN News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 03:57:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 09:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 09:06:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 10:15:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 09:25:27 PM
- Lifecore Biomedical Announces Cooperation Agreement with 22NW • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:00:18 PM
- Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination • GlobeNewswire Inc. • 05/30/2024 08:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/14/2024 08:05:19 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/04/2024 12:59:19 AM
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ • GlobeNewswire Inc. • 04/16/2024 11:00:00 AM
- Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:30:40 PM
- Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 07:16:19 PM
- Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer • GlobeNewswire Inc. • 10/23/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 12:30:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:15:36 PM
- Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 • GlobeNewswire Inc. • 09/27/2023 12:30:00 PM
FEATURED North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • Aug 5, 2024 9:00 AM
Fifty 1 Labs, Inc. and All-In-Extracts Announce Joint Venture to Develop and Release New Testosterone Boosting Supplement • BLEG • Aug 5, 2024 8:30 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM